The present invention relates to the field of the diagnosis and/or prognosis of eosinophilic esophagitis (EoE) in saliva, specifically diagnosis and/or prognosis for the detection and quantification of the expression level of EoE biomarker genes present in the saliva of subjects.

TYPE OF DEVELOPMENT

Diagnostic and/or prognostic tool.

DESCRIPTION

Eosinophilic Oesophagitis (EoE) is an inflammatory disease characterised by the presence of a large number of eosinophils in the oesophagus. A rise in EoE incidence and prevalence is becoming a major cause of upper gastrointestinal morbidity in children and adults The symptoms may be mistaken for other diseases (such as celiac disease). This may lead to diagnostic delays and difficulties.

Delayed diagnosis seems associated with fibrostenotic disease complaints, suggesting timely recognition of the disease may influence its clinical course.

Currently EoE final diagnosis is achieved using invasive methods by means of upper gastrointestinal endoscopy and biopsies with high time and economic cost.

This invention provides a non-invasive method for selective testing of patients with higher risk of developing EoE, facilitating diagnostic processes, reducing the number of endoscopies, and enabling better management of patients.

INDICATION

• Selective diagnostic of Eosinophilic Oesophagitis (EoE).
• Follow-up Evolution / Prognosis of patients with Eosinophilic Oesophagitis (EoE).

NOVELTY/ADVANTAGE

• Selective diagnostic.
• Non-invasive method.
• Quick.
• Low cost.

INFORMATION

• Reference: TestSalivaEosinofilos2 (20BIO01)
• Research group: Genetics.
• Main researcher: Jose Ramon Bilbao Catala.
• Contact: Knowledge/Technology Transfer Office, iproperty.otri@ehu.eus

IPR STATUS

• Patent Application: P202030978, PCT/ES2021/070706
• Priority date: 29/09/2020
• Applicants: Administration of the Autonomous Community of the Basque Country. UPV/EHU, SESCAM and CIBER.

COOPERATION GOAL

• Company interested in licensing and marketing the product.